Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021

Keywords

• Anti-Infective Agents/pharmacology/therapeutic use
• Arterial Pressure
• Biomarkers
• Blood Glucose
• Cardiotonic Agents/therapeutic use
• Critical Care/*standards
• Diagnosis, Differential
• Drug Administration Routes
• Drug Administration Schedule
• Electronic Health Records/standards
• Erythrocyte Transfusion/standards
• Fluid Therapy/standards
• Hemodynamics/physiology
• Humans
• Immunoglobulins/therapeutic use
• Intensive Care Units/standards
• Lactic Acid/blood
• Organ Dysfunction Scores
• Practice Guidelines as Topic
• Reference Values
• Renal Replacement Therapy/standards
• Respiration, Artificial/standards
• Resuscitation/standards
• Sepsis/*diagnosis/drug therapy/*therapy
• Severity of Illness Index
• Shock, Septic/diagnosis/therapy
• Time-to-Treatment
• Vasoconstrictor Agents/therapeutic use
• Society and is the chair of the guidelines in intensive care, development and
• evaluation (GUIDE) Group, McMaster University Canada. Dr. Antonelli received funding
• from GE, Toray-Estor, Baxter, Pfizer, Orion, Maquet, and Fisher and Paykel
• he was
• on the board of Baxter and Pfizer, and is a member of the executive committee and
• past president of Società Italiana di Anestesia Rianimazione e Terapia Intensiva
• (SIAARTI). Dr. French contributed to the ANZICS Guidelines and the National COVID-19
• Guidelines. Dr. Machado is a member of the Executive Committee for the Basics Study
• (for which Baxter provided the drugs and logistics) and AMIB. Dr. McIntyre is a
• member of the Canadian Critical Care Society and serves on the Surviving Sepsis
• Campaign Steering Committee. Dr. Ostermann is a council member of the Intensive Care
• Society UK and member of the Renal Association UK and World Sepsis Alliance. Dr.
• Prescott is a member of the ATS Critical Care Program Committee. Dr. Simpson is the
• president-elect and Chair of CHEST, is a member of the board of directors and
• medical director of Sepsis Alliance, and Chair of the Sepsis Institute Advisory
• Board. Dr. Wiersinga is a member of ISF, ESCIMID, and SWAB. Dr. Angus received
• funding from Ferring Pharmaceuticals, Inc and ALung Technologies, Inc. Dr. Beale
• provides consultancy services for Philips Healthcare with his time billed by his
• institution. Dr. Beilman is the president of the Surgical Infection Society. Dr.
• Belley-Cote received grants from Roche and Bayer and is a panel member on the Saudi
• Critical Care Society COVID-19 Thrombosis Guidelines. Dr. Cecconi is a consultant
• for Edwards Lifesciences, Cheetah Medical, and Directed Systems and is President of
• the European Society of Intensive Care Medicine. Dr. Coz is a board member of the
• American College of Chest Physicians. Dr. De Waele consulted for Accelerate, Bayer,
• Grifols, Pfizer, and MSD with all honoraria paid to Ghent University
• he is a Senior
• Clinical Investigator with the Research Foundation Flanders. Dr. Dellinger serves as
• an expert witness on occasional medical legal case reviews. Dr. Doi is a member of
• the Japanese Society of Intensive Care Medicine. Dr. Du is a member of the Chinese
• Society of Critical Care Medicine and the Chinese College of Intensive Care
• Medicine. Dr. Ferrer received funding from Grifols, MSD, Pfizer, Shionogi, Toray,
• Jafron, and Cytosorbents
• he is a member of SEMICYUC. Dr. Gomersall is a member of
• an educational subgroup of the International Forum of Acute Care Trialists. Dr.
• Hodgson is a member of the Australian National Health and Medical Research Council
• guidelines (COVID-19) and leading funded trials in early rehabilitation and ECMO.
• Dr. Møller contributed to guideline work for DASAIM, SSAI, GUIDE, and ESA. Dr.
• Iwashyna is a member of the ATS, the NIH, and an informal (unincorporated)
• organization called the Critical and Acute Illness Recovery Organization. Dr. Jacob
• co-directs the African Research Collaboration on Sepsis (ARCS, funded by UK National
• Institute for Health Research, sponsored by Liverpool School of Tropical Medicine),
• he is Secretary General for the African Sepsis Alliance, and is a technical expert
• for the World Health Organization panels. Dr. Kleinpell is a board member of the
• World Federation of Intensive and Critical Care, American Nurses Credentialing
• Center, and the Tennessee Nurses Association Political Action Committee. Dr. Klompas
• received funding from Up-to-Date
• he is a member of the guidelines committees of the
• Infectious Disease Society of America (IDSA) and Society of Healthcare
• Epidemiologists of America (SHEA). Dr. Koh is a member of The Korean Society of
• Critical Care Medicine, The Korean Academy of Tuberculosis and Respiratory Diseases,
• The Korean Society of Medical Ethics, and the Asia Ventilation Forum. Dr. Kumar
• served as an expert witness regarding a lethal dose of narcotics. Dr. Kwizera is
• president of the Intensive Care Society of Uganda and PRO for the Association of
• Anesthesiologists of Uganda. Dr. Lobo received funding from Pfizer, MSD, Edwards,
• and Nestle
• she is the principal investigator in new antibiotics research led by
• CROs/industry
• she is a member of the AMIB Executive Board and was elected president
• for 2020-2021. Dr. McGloughlin is a member of ANZICS (Australian New Zealand
• Intensive Care Society). Dr. Mehta participated in two non-interventional studies by
• ISCCM-Hermes and Indicaps. Dr. Mer has been an invited speaker for educational talks
• in industry-sponsored symposia for which honoraria was received
• he is the current
• Vice President of the Southern African Society of Thrombosis and Haemostasis
• (SASTH), and is involved in annual congress organization
• he is an invited author of
• the Global guidelines for the diagnosis and management of mucormycosis: an
• initiative of the European Confederation of Medical Mycology in cooperation with the
• Mycoses Study Group Education and Research Consortium. Dr. Nunnally is the treasurer
• of SOCCA, committee member of ASA, NYSSA, IARS, AUA, and SAAAPM and serves on the
• American College of Critical Care Medicine Board of Regents. Dr. Oczkowski is a
• member of the European Respiratory Society, and contributed to the High Flow Nasal
• Cannula Guidelines, the Non-Invasive Ventilation in COPD Guidelines. Dr. Osborn
• received funding from Viven Inc, Inflammatrix, Beckman, and the Foundation for
• Barnes Jewish Hospital
• she is on the advisory board for Beckman, Inflammatix, and
• Viven
• she is a member of the American College of Emergency Physicians, American
• College of Chest Physicians, American Medical Association, Society of Academic
• Emergency Medicine, and American Academy of Emergency Physicians
• she served as an
• expert witness in a case related to viral as compared to bacterial sepsis. Dr.
• Papathanassoglou is a member of the World Federation of Critical Care Nurses (Editor
• of Journal) and the Canadian Association of Critical Care Nurses. Dr. Perner
• received a research grant from Pfizer Denmark. Dr. Puskarich is the co-inventor of a
• patent to assess L0carnitine drug responsiveness in sepsis (USPO 10330685)
• he is a
• member of the Society for Academic Emergency Medicine, American College of Emergency
• Physicians (ACEP)
• he was invited to a recently gathered ACEP early sepsis treatment
• policy task force asked to develop specialty recommendations for early sepsis
• treatment. Dr. Roberts received funding from MSD, The Medicines Company, Cardeas
• Pharma, Biomerieux, QPEX, Cipla, and Pfizer
• he consulted for MSD, QPEX, Discuva
• Ltd, Accelerate Diagnostics, Bayer, Biomerieux, UptoDate, and Australian Therapeutic
• Guidelines
• he is a member of the Society of Hospital Pharmacists of Australia
• Leadership Committees for Critical Care and Infectious Diseases and the Lead of
• Sepsis Working group for the International Society of Anti-infective Chemotherapy.
• Dr. Schweickert is a paid consultant to the American College of Physicians (last
• performed in Spring, 2019). Dr. Seckel volunteers for AACN and is a paid consultant
• to revise online Critical Care Orientation. Dr. Sevransky received funding from the
• Marcus Foundation- PI VICTAS Trial and serves on the American College of Critical
• Care Medicine Board of Regents. Dr. Welte received funding from Astellas,
• AstraZeneca, Boehringer, Basilea, Bayer, Berlin-Chemie, Grifols, Infectopharm,
• Mundipharma, MSD, Novartis, Pfizer, DFG, EU, BMBF, and Insmed
• he is on the advisory
• board for AstraZeneca, Boehringer, Bayer, Gilead, GSK, Insmed, Novartis, Pfizer,
• Roche
• he is a member of the European Respiratory Society, German Society of
• Pneumology, and Paul Ehrlich Gesellschaft. Dr. Zimmerman is a member of the ACP,
• AACP, and WFPICCS. Dr. Levy is a legal consultant for a few cases involving sepsis
• and serves as co-chair of the Surviving Sepsis Campaign Steering Committee. The
• remaining authors have disclosed that they do not have any potential conflicts of
• interest.